131 related articles for article (PubMed ID: 35319443)
1. Health Services and Policy Research in Canada: An Editor's Reflections.
Lexchin J
Healthc Policy; 2022 Feb; 17(3):42-48. PubMed ID: 35319443
[TBL] [Abstract][Full Text] [Related]
2. Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: An observational study.
Moriarty F; Larkin J; Fahey T
Health Policy; 2021 Oct; 125(10):1297-1304. PubMed ID: 34429238
[TBL] [Abstract][Full Text] [Related]
3. Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016.
Stoll M; Hubenschmid L; Koch C; Lieb K
BMJ Open; 2020 Sep; 10(9):e037395. PubMed ID: 32948560
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
Rickard E; Ozieranski P; Mulinari S
Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
[TBL] [Abstract][Full Text] [Related]
6. Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada.
Lexchin J
Int J Health Policy Manag; 2022 Oct; 11(10):2046-2053. PubMed ID: 35021614
[TBL] [Abstract][Full Text] [Related]
7. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.
Mulinari S; Ozieranski P
BMJ Open; 2018 Oct; 8(10):e023094. PubMed ID: 30344175
[TBL] [Abstract][Full Text] [Related]
8. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
[TBL] [Abstract][Full Text] [Related]
9. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.
Parker L; Karanges EA; Bero L
BMJ Open; 2019 Feb; 9(2):e024928. PubMed ID: 30782921
[TBL] [Abstract][Full Text] [Related]
10. Sunshine Act: shedding light on inaccurate disclosures at a gynecologic annual meeting.
Thompson JC; Volpe KA; Bridgewater LK; Qeadan F; Dunivan GC; Komesu YM; Cichowski SB; Jeppson PC; Rogers RG
Am J Obstet Gynecol; 2016 Nov; 215(5):661.e1-661.e7. PubMed ID: 27319366
[TBL] [Abstract][Full Text] [Related]
11. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
[TBL] [Abstract][Full Text] [Related]
12. Physicians' attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey.
Stoll M; Hubenschmid L; Koch C; Lieb K; Egloff B
BMJ Open; 2022 Jun; 12(6):e055963. PubMed ID: 35750457
[TBL] [Abstract][Full Text] [Related]
13. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016).
Ozieranski P; Csanádi M; Rickard E; Mulinari S
BMJ Open; 2020 Sep; 10(9):e037351. PubMed ID: 32950962
[TBL] [Abstract][Full Text] [Related]
14. Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries.
Fabbri A; Santos A; Mezinska S; Mulinari S; Mintzes B
Int J Health Policy Manag; 2018 Jun; 7(6):504-509. PubMed ID: 29935127
[TBL] [Abstract][Full Text] [Related]
15. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
BMJ Open; 2021 Dec; 11(12):e053138. PubMed ID: 34916317
[TBL] [Abstract][Full Text] [Related]
16. Discrepancies between author- and industry-reported disclosures of financial relationships at an annual gynecologic oncology research meeting.
Guo XM; Cowan M; Folsom S; Ehimiaghe E; Persenaire C; Barber EL; Tanner EJ
Gynecol Oncol; 2021 Jan; 160(1):260-264. PubMed ID: 33187761
[TBL] [Abstract][Full Text] [Related]
17. Drug company payments to General Practices in England: Cross-sectional and social network analysis.
Saghy E; Mulinari S; Ozieranski P
PLoS One; 2021; 16(12):e0261077. PubMed ID: 34874975
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of post-publication Financial Conflict of Interest corrections in medical research: A secondary analysis of pharmaceutical company payments to the authors of the CREATE-X trial report in the New England Journal of Medicine.
Ozaki A; Saito H; Sawano T; Shimada Y; Tanimoto T
Bioethics; 2021 Sep; 35(7):704-713. PubMed ID: 34137057
[TBL] [Abstract][Full Text] [Related]
19. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
Kang SY; Bai G; Karas L; Anderson GF
Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
[TBL] [Abstract][Full Text] [Related]
20. Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.
Rickard E; Carmel E; Ozieranski P
BMJ Open; 2023 Mar; 13(3):e061591. PubMed ID: 36990486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
